BCM
BBNX

Bayesian Capital Management’s Beta Bionics BBNX Stock Holding History

Bayesian Capital Management’s Portfolio BBNX Stock Details BBNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$100K Buy
+10,017
New +$148K 0.12% 131

Other funds holding BBNX

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Bayesian Capital Management's BBNX Position: Q1 2026 in Review

Bayesian Capital Management opened a new position in Beta Bionics (BBNX) in Q1 2026: 10,017 shares worth $100K. The stake represents 0.12% of the portfolio and ranks #131 among its holdings.

130 funds tracked by Wall St. Rank hold BBNX as of Q1 2026.

  • Bayesian Capital Management held 10,017 shares of Beta Bionics worth $100K as of Q1 2026.
  • Beta Bionics was a new Bayesian Capital Management position in Q1 2026.
  • Beta Bionics made up 0.12% of Bayesian Capital Management's portfolio in Q1 2026, its #131 holding.
  • 130 funds tracked by Wall St. Rank held Beta Bionics as of Q1 2026.

Based on Bayesian Capital Management's 13F filing for Q1 2026, filed 15 May 2026.